Skip to main content
PLOS One logoLink to PLOS One
. 2020 Dec 14;15(12):e0242408. doi: 10.1371/journal.pone.0242408

Demonstration of a fast and easy sample-to-answer protocol for tuberculosis screening in point-of-care settings: A proof of concept study

Nasir Ali 1,2, Graziele Lima Bello 3,4, Maria Lúcia Rosa Rossetti 3,4, Marco Aurelio Krieger 1,2,5, Alexandre Dias Tavares Costa 1,5,*
Editor: Seyed Ehtesham Hasnain6
PMCID: PMC7735633  PMID: 33315885

Abstract

We sought to develop a smooth and low cost sample preparation and DNA extraction protocol, streamlined with a ready-to-use qPCR in a portable instrument to overcome some of the existing hurdles. Several solutions were evaluated as to their ability to liquefy a mucin-based matrix. Each liquefied matrix, supplemented with either Mycobacterium tuberculosis (MTB) H37Rv strain DNA or intact cells, was aliquoted onto a filter paper embedded with solubilizing agents, and was subsequently dried up. Most of the nucleic acids, including genomic DNA from the bacilli and the host, binds to the filter paper. Next, several protocols were evaluated to elute the DNA from the paper, using qPCR to detect the insertion sequence IS6110, a M. tuberculosis complex genomic marker. The limit of detection (LOD) of the best protocol was then evaluated using parallel seeding and colony counting. The protocol was also evaluated using seventeen sputum samples, previously characterized by the GeneXpert or culture. Two instruments (the ABI7500 Standard and the Q3-Plus system) and two reagents storage formats (frozen or ready-to-use) were evaluated. Solutions containing guanidine isothiocyanate exerted the best liquefying effect on the mucin-based matrix extracted from one 6-mm punches, followed by a brief incubation at 95°C. The resulting DNA contained impurities, but a simple 1:10 dilution elicited the detection of MTB and human genomic targets. The described protocol presented an apparent LOD of 02 CFU/mL of MTB. Challenging the protocol with previously characterized samples showed substantial agreement with GeneXpert MTB/RIF results (sensitivity of 90%, agreement of 88.9%, kappa coefficient of 0.77), and moderate agreement with culture results (sensitivity of 100%, agreement of 78.9%, kappa coefficient of 0.58). This work presents a sensitive proof–of-concept protocol for sputum liquefaction and decontamination followed by a simple DNA extraction procedure, in which the extraction steps are streamlined with a ready-to-use qPCR in a portable instrument that can be employed in low infrastructure settings.

Introduction

Tuberculosis (TB), caused by the bacillus Mycobacterium tuberculosis (MTB), is one of the leading causes of mortality from a single infectious microorganism, which disproportionately affects low and middle-income countries. In 2016, 1.7 million people have died and 10.4 million been fell ill due to TB, while 56% of the cases were from only five countries: India, Indonesia, China, Philippines and Pakistan [1]. Many diagnostic tests already exist, but a large gap of 4.1 million people without proper TB diagnosis still poses a serious global health challenge [2]. TB diagnosis is routinely performed by sputum culturing, smear microscopy, chest x-rays, the tuberculin skin test, or nucleic acid-based molecular tests [3]. Although nucleic acid amplification and detection techniques such as PCR and LAMP have open a new era of specific and sensitive diagnostic testing, these tests are mostly available in developed countries and resource rich areas. Reasons for the lack of widespread use are many, but costs, cumbersome sample preparation and nucleic acid extraction protocols as well as fragile instruments are the most prominent ones [3, 4].

Sample preparation has always been a challenge for molecular assays as well as a bottleneck in translating complex molecular based tests to easy-to-use point of care products [4]. Moreover, the sputum samples used in TB diagnosis pose additional challenges, such as the probability of being highly contagious as well as its high viscosity. Sputum culture is an important diagnostic tool in TB control programs, because it is more sensitive than smear microscopy and facilitates drug susceptibility testing, even though its results take too long to obtain. However, because sputum samples pass through the oropharynx during collection, culture contamination limits the diagnostic yield of sputum culture for TB. To overcome this problem, the World Health Organization (WHO) standard procedure for sputum decontamination and liquefaction recommends mixing the sample with a solution containing N-acetyl-L-cysteine and sodium hydroxide (NALC/NaOH solution) for no more than 15–20 minutes [5, 6]. WHO sample treatment principles are two: (1) the short exposure to NaOH kills all bacteria present in the sputum sample with the exception of M. tuberculosis, and (2) the mucolytic agent NALC reduces the disulfide bonds of the extracellular matrix components of the sputum, liquefying the high protein sample, thus allowing easier manipulation and the use of lower concentrations of NaOH.

Chaotropic agents such as urea or guanidine (hydrochloride or isothiocyanate) are known to disrupt non-covalent bonds within biological molecules, such as those that hold together proteins tertiary structure or lipid bilayers. Indeed, chaotropic agents have long been used to disrupt cellular structures for nucleic acid extraction in molecular biology [4] or to increase protein extraction yield in biochemical protocols [7]. Interestingly, high concentrations of guanidine hydrochloride have been shown to inactivate M. tuberculosis bacilli in sputum samples following exposure to common lysis buffers contained in nucleic acid extraction kits [8].

Most of the molecular assays developed to date depend on dedicated laboratory space, complex protocols, as well as highly sophisticated and delicate instruments. Although some tests have been developed for use in low infrastructure settings, their costs are still prohibitive for mass screening in countries where tuberculosis is endemic. A rapid, simple, efficient, less expensive and ideally equipment-free sample preparation would not only bring down the cost of molecular assays but also mitigate the challenge of access to low-resource settings [9, 10]. Furthermore, the reagents used in molecular assays require special storage and transportation, which further increase their costs [11, 12]. Largely, the successful integration of sample preparation with ready-to-use reagents and portable qPCR systems would solve the main hurdles in point of care testing [9, 10, 13].

We sought to develop a procedure that uses the whole sputum sample (avoiding sample heterogeneity) to screen for the IS6110 insertion element sequence of Mycobacterium complex [14]. We evaluated several chaotropic agents for their ability to liquefy sputum-like porcine mucin-based samples, which are common substitutes for sputum in research settings [15]. The liquefied mixture was stored in a detergent-containing commercial filter paper, and several subsequent steps for DNA extraction were evaluated. Extracted DNA was assayed for the presence of M. tuberculosis DNA using ready-to-use qPCR reagents preloaded onto a portable thermocycler. Lastly, the full protocol, from sample liquefaction and filter paper DNA extraction to detection by qPCR, was evaluated using a small number of patient samples, and results were then compared to those obtained by a different molecular method (GeneXpert MTB/RIF) as well as culture.

The proof of concept protocol presented here is a simple and straightforward diagnostic solution that could be employed to screen MTB-suspected patients in low-resource areas, and the positive results warrant future larger studies.

Materials and methods

Clinical specimens

Sputum samples were collected from new patients attending the Department of Thisiology and Leprosy of the city of Canoas (RS, Brazil) in two consecutive days according to WHO and the Brazilian Ministry of Health recommendations [16]. Inclusion criteria were no previous treatment and ability to produce a minimal sample volume per day (500 μL). Exclusion criteria were previous treatment and inability to produce enough sample volume. Day 01 samples were analyzed by culture and the GeneXpert MTB/Rif assay. The remaining volume of day 01 sample was pooled with day 2 sample and 500 μL were used for the evaluation of the new paper-based DNA extraction protocol. Non-TB samples were defined by negative results on the GeneXpert MTB/RIF assay and culture. The Ethics Committee for Research in Humans of the Universidade Luterana do Brasil (Canoas, Brazil) approved the present study. Samples were part of the diagnostic routine of the Department of Thisiology and Leprosy and would be discarded. Therefore, the ethics committee did not require informed consent from the patients (CAAE: 70697116.7.0000.5349, #1.786.666). A general workflow of the whole procedure is presented in Fig 1.

Fig 1. Schematic representation of the experimental workflow.

Fig 1

Patients attending the Department of Thisiology and Leprosy of the Universidade Luterana do Brasil (ULBRA) were included in the study if had not had previous TB treatment and were able to produce a minimum of 500 μL of sputum per collection day. Accordingly, patients were excluded if had previous TB treatment or were unable to produce the minimal sample volume. Samples were collected on two consecutive days and were subjected to the GeneXpert MTB/Rif assay and culture. Next, eight liquefying solutions and six elution protocols were evaluated using the same samples. Eluted DNA were evaluated by two qPCR instruments and two reagents’ storage formats.

Solutions used in optimization protocols

A 20% mucin solution (cat# M1778, Sigma Aldrich, Missouri, US) was prepared in a sterile 15 mL conical tube. After thorough mixing, the tube was placed in water bath for 2 hours at 55°C. Consistency of mucin solution was checked at intervals of 30 min with naked eye and gentle shaking to ensure proper solubilization. The tubes were placed at room temperature (21–23°C) for 4 hours for cooling, when mucin solution consistency was checked for its resemblance to sputum consistency. The solution was divided into 500 μL aliquots and stored at 2–8°C in refrigerator for future use. The initial viscosity of porcine mucin was rated as ++++, and then from ++++ (most viscous, or unaltered) to + (least viscous, or liquefied) after the chemical treatments. Viscosity was observed and subjectively measured with the naked eye while gently agitating the tubes. Relative viscosity was performed by two researchers (NA and ADTC) in three independent experiments per researcher. Eight different compositions of the liquefying solution, also called “Solution 01” hereafter, were evaluated (Table 1). The details for preparation of each solution are outlined below and on Table 1. NALC/NaOH solution was prepared by mixing equal volumes of 6% NaOH (3 grams NaOH in 50 mL distilled water) and 2.9% sodium citrate (1.45 grams Na-citrate in 50 mL distilled water). The solution was sterilized by autoclaving at 121°C for 15 minutes and kept in the refrigerator until needed, according to WHO protocols [6]. Immediately before use, 0.5% (i.e., 0.25 grams) N-acetyl-L-cysteine (cat# A7250, Sigma Aldrich, Missouri, USA) was added to 50 mL of NALC/NaOH and dissolved by gentle inversion. The resulting solution was stored at 2–8°C until 15 minutes prior to use, when it should be warmed up to room temperature [6]. GSCN solution (6 M) was prepared by dissolving 17.72 grams of guanidine thiocyanate (GSCN, cat# G9277, Sigma Aldrich, Missouri, USA) in 10 mL of a 0.5 M EDTA solution (pH 8.0) in a 50 mL conical tube. The tube was heated at 65°C for 1 hour with occasional inversion to help homogenization. After incubation, volume was brought up to 25 mL with 0.5 M EDTA (pH 8.0) and the total volume was divided into 500 μL aliquots. Urea solution (8 M) was prepared by dissolving 48.05 grams of urea (cat# U5378, Sigma Aldrich, Missouri, USA) in 60 mL of distilled water. After the reagent was completely dissolved, the volume was adjusted to 100 mL with distilled water. Triton X-100 (10%) was prepared by diluting 5 mL of 100% Triton X-100 (cat# T8787, Sigma Aldrich, Missouri, USA) in 45 mL distilled water. SDS (10%) was prepared by dissolving 0.5 grams of sodium dodecyl sulphate (cat# L3771, Sigma Aldrich, Missouri, USA) in 50 mL distilled water. Nonidet P-40 substitute, or NP-40, (10%) was prepared by diluting 5 mL of 100% NP-40 substitute (cat# 74385, Sigma Aldrich, Missouri, USA) in 45 mL distilled water. All surfactant solutions were homogenized by gentle inversion to avoid formation of bubbles. Hydrochoric acid (HCl, cat# H1758, Sigma Aldrich, Missouri, USA) was diluted from the concentrated stock (36.5–38%, approximately 36 M) to 1 M in distilled water and stored at room temperature. Solution 02 consisted of commercial solution of Tris-EDTA (TE) pH 8.0 (cat# AM9856, Ambion, Massachusetts, USA). Except where noted, all solutions were stored at room temperature.

Table 1. Liquefaction of mucin with different chemicals.

Tube # Mucin NALC/ NaOH PBS GSCN Urea TX100 / SDS / NP40 Total Liquefaction Before/After
[Stock] 20% (w/v) 0.5% / 3% (w/v) 100 mM 6 M 8 M 10% - -
1 500μL 500μL 500μL - - - 1500μL ++++ / +
2 500μL 500μL 500μL 400μL 400μL 100μL 2000μL ++++ / +
3 500μL - - 200μL 200μL 100μL 1000μL ++++ / ++
4 500μL - - 500μL 500μL 200μL 1700μL ++++ / ++
5 500μL - - 250μL 250μL 100μL 1100μL ++++ / ++
6 500μL - - 500μL - - 1000μL ++++ / +
7 500μL - - - 500μL - 1000μL ++++ / ++
8 500μL - - - - 200μL 700μL ++++ / +++
9 500μL - - 300μL 100μL 50μL 1000μL ++++ / ++

Chemicals and their respective concentration and volumes used to produce different liquefying solutions. Porcine mucin was used as sputum substitute and its viscosity was classified with the naked eye by gentle agitation of the tube. Viscosity of each solution was classified from the most viscous (++++) to less viscous (+).

Sample preparation and application onto FTA card

One mL of the sputum sample was mixed and thoroughly homogenized with 400 μL of the liquefying solutions (Table 1) for 30 seconds in vortex. The “Solution 01” with the best liquefying ability (GSCN 6M), as shown in Table 1 (tube #6), was used in all the next steps. This solution, GSCN 6M, will be referred to as Solution 01 for the remaining steps of the study. The homogenized mixture (“sample plus Solution 01”) was uniformly applied onto a FTA ELUTE Micro Card (cat# WB120401, GE Health Care Life Sciences, Chicago, US). The card was allowed to dry for 1 hour at room temperature (21–23°C).

DNA elution protocols

Six DNA elution protocols were evaluated (Table 2). The FTA ELUTE Micro Card has four circular pre-marked areas, each with 11 mm of diameter. Either one entire circular area or one disc of 6 mm in diameter were punched off the FTA card that was spotted with sample. The punched discs were collected in a clean 1.5 mL tube. Five hundred microliters (500 μL) of Solution 02 were added to each tube, which was either vortexed for 3 times of 5 seconds with 5-seconds intervals or sonicated in water bath for 3 times of 15 seconds with 5-seconds intervals. Next, tubes were incubated at room temperature or 95°C for 5 minutes. Tubes were cooled down to room temperature, and the supernatants containing the extracted DNA were collected into a new tube. The supernatant was used for qPCR analyses or stored at -20°C for future use. The remaining of the FTA ELUTE Micro Card was stored at room temperature for future use. For protocol optimization, DNA from the each sample was extracted 2–3 times for each experimental condition. The concentration of the eluted DNA was measured spectrophotometrically at 260 nm on a Nanodrop 2000 (Thermo Fisher Scientific, USA).

Table 2. Steps of each of the six different DNA elution protocols evaluated in the present work.

Protocol 1 Protocol 2 Protocol 3 Protocol 4 Protocol 5 Protocol 6
1. Take the whole circle (11 mm) 1. Take the whole circle (11 mm) 1. Take one punch (6 mm) 1. Take one punch (6 mm) 1. Take the whole circle (11 mm) 1. Take one punch (6 mm)
2. Add 500μL H2O or TE pH 8.0 2. Add 500μL H2O or TE pH 8.0 2. Add 500μL H2O or TE pH 8.0 2. Add 500μL H2O or TE pH 8.0 2. Add 500μL H2O or TE pH 8.0 2. Add 500μL H2O or TE pH 8.0
3. Vortex 3x for 5 sec 3. Vortex 3x for 5 sec 3. Vortex 3x for 5 sec 3. Vortex 3x for 5 sec 3. Water bath sonication (3x 15 sec) 3. Water bath sonication (3x 15 sec)
4. Incubate at 95°C /5 min 4. Room temperature / 5 min 4. Incubate at 95 oC / 5 min 4. Room temperature / 5 min 4. Room temperature / 5 min 4. Incubate at 95°C / 5 min
5. Collect supernatant 5. Collect supernatant 5. Collect supernatant 5. Collect superrnatant 5. Collect supernatant 5. Collect supernatant
6. Run qPCR 6. Run qPCR 6. Run qPCR 6. Run qPCR 6. Run qPCR 6. Run qPCR

Each protocol was devised to evaluate one or a combination of chemical and physical properties of each step to maximize elution of DNA from the FTA cards. In bold, the protocol that yielded the best results (protocol #3).

Limit of Detection (LOD): Colony forming units in parallel to qPCR

Reference strain M. tuberculosis H37Rv colonies cultivated in Ogawa-Kudoh medium were collected and homogenized with glass beads. The turbidity of the bacterial solution was compared to the turbidity of the McFarland number 1 standard (widely used in microbiology, especially for conventional anti-biograms). Subsequently, ten-fold serial dilutions were performed from the concentrated cell suspension, and individual mucin samples of 500 μL were spiked with 30 μL of each dilution. The whole volume was equally distributed onto individual FTA ELUTE Micro Cards after incubation with Solution 01 (see “Sample preparation and application onto FTA card”). The procedure was performed in duplicate for each concentration. The most efficient DNA extraction protocol as determined in section “DNA elution protocols” (protocol #3, in bold in Table 2), in parallel with the second best (protocol #4), was performed on each FTA card, and qPCR assays on the ABI7500 or the Q3-Plus system were used to evaluate the Ct for each dilution. The same procedure was performed in parallel and spiked mucin samples were plated in duplicates in petri dishes containing 7H10/OADC medium. Colonies were counted using a semi-quantitative scale, according to the guidelines of the Brazilian Surveillance Laboratory for Tuberculosis and other Mycobacteria [16].

Gelification of qPCR reagents

Gelification of the qPCR reagents was performed by adding a gelification solution in substitution for water, according to published protocols The final concentration of each component of the gelification mixture used in this study was trehalose 160 mg/mL, melezitose 80 mg/mL, glycogen 40 mg/mL and lysine 0.15 mg/mL. all qPCR reagents (enzymes, buffers, oligonucleotides, dNTPs, etc.) and 5 μL of in substitution for molecular-grade water in [12, 1719]. The gelification solution contains three classes of components, each with specific functions within the mixture and the process: (i) trehalose and melezitose (400 mg/mL each), to protect the biomolecules from the desiccation process by stabilizing and reducing the activity of water in the solution; (ii) lysine (0.75 mg/mL), a free radical scavenger which inhibits oxidizing reactions between carbonyl or carboxyl groups and the biomolecule’s amino or phosphate groups; and (iii) glycogen (200 mg/mL), an inert polymer which creates a broader protective matrix. These components define a sol-gel mixture that prevent the loss of the tertiary or quaternary structure during the desiccation process, thus helping maintaining the biomolecules’ activity upon rehydration [12, 17]. The final concentration of each component of the gelification mixture used in this study was trehalose 160 mg/mL, melezitose 80 mg/mL, glycogen 40 mg/mL and lysine 0.15 mg/mL. The qPCR mix containing all qPCR reagents (enzymes, buffers, oligonucleotides, dNTPs, etc.) and 5 μL of the gelification solution in substitution for molecular-grade water was manually aliquoted into each reaction well. Next, the reaction vessels (either the ABI7500 plastic 96-well plates or the Q3-Plus silicon chips) were submitted to vacuum (30 ± 5 mbar) under controlled temperature (30 ± 1°C) to gelify the reagents. For all experiments, gelified reactions were stored at 2–8°C for up to 7 days.

Experimental conditions for qPCR

For detection of MTB, primers and probe for the IS6110 insertion element of the Mycobacterium complex were purchased as a custom Taqman® gene expression assay (Table 3) (Thermo Scientific, California, USA). Regular or gelified reactions were performed on a standard ABI7500 instrument (Applied Biosystems) or on the portable prototype instrument Q3-Plus [20]. The Q3-Plus system has small dimensions (7 × 14 × 8.5 cm), weighs only 300 grams, performs the thermal cycles in a disposable silicon chip, and can be operated with any small portable computer. The reactions contained the Multiplex PCR Mastermix (IBMP, Curitiba, Brazil) and MTB Taqman Oligomix (assay name IS6110-A, assay ID: AIPACNK, Thermo Scientific, USA). Regular and gelified reactions followed the same cycling conditions as well as analysis parameters. In the ABI7500 instrument, reactions were standardized to a final volume of25 μL, considering the addition of 5 μL of sample (extracted DNA), and the cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, followed by 45 cycles of 95°C for 15 seconds and 60°C for 60 seconds. Baseline and threshold were set to automatic. In the Q3-Plus instrument, 1 μL of the extracted DNA was added to a final volume of 5 μL, and the cycling conditions were: 80°C for 10 seconds, 97°C for 60 seconds, followed by 45 cycles of 97°C for 20 seconds and 62°C for 60 seconds. The optical parameters for the FAM channel in the Q3-Plus system were exposure time of 1 second, led power of 3 and analog gain of 15, while for the VIC channel the optical parameters were exposure time of 2 seconds, led power of 8, and analog gain of 14. Baseline is automatic and threshold was set to 15 arbitrary units of fluorescence. Reactions on both instruments were also supplemented with oligonucleotides for the detection of the human 18S rRNA gene, as an internal reaction control (Table 3). The detection of a human gene confirms the presence of the sample in the reaction, as well as controls for the presence of possible contaminants or inhibitors [11, 21].

Table 3. Sequence of primers and probes used for detection of the genomic MTB target IS6110 and of the human gene 18S rRNA.

Name Sequence (5´-3´)
IS6110 Fw CAGGACCACGATCGCTGAT
IS6110 Rv TGCTGGTGGTCCGAAGC
IS6110 Probe FAM-TCCCGCCGATCTCG-MGB
18S Fw TGCGAATGGCTCATTAAATC
18S Rv CGTCGGCATGTATTAGCTCT
18S Probe VIC-TGGTTCCTTTGGTCGCTCGCT-BHQ1

Statistical analysis

Reactions on the ABI7500 instrument were performed in triplicates, and reactions on the Q3-Plus instrument were performed in duplicates (optimization protocols) or quadruplicates (patient samples). The Cohen’s kappa coefficient was calculated between the Q3-Plus or ABI7500 results obtained with the chosen protocol and the results obtained with GeneXpert or culture, using these latter methods as the gold standard with a 95% CI (confidence interval). The coefficient was used to test the agreement between the diagnostic methods/instruments, and Kappa results were interpreted according to [22]: 1.00–0.81 almost perfect, 0.80–0.61 substantial, 0.60–0.41 moderate, 0.40–0.21 fair and ≤0.20 slight agreement. Student t-test with a significance level of 0.05 was used to evaluate the difference between results obtained with the ABI7500 and the Q3-Plus system. The LOD for the DNA extraction protocols was estimated by qPCR in parallel to colony growth.

Results

Sample liquefaction and protocol optimization

We hypothesized that concentrated GSCN and other chemicals would liquefy a sputum-like matrix consisting of porcine mucin. GSCN (6 M) was used alone, or mixed with other chaotropic or surfactant chemicals, such as urea (8 M), Triton X-100 (10%), SDS (10%), or NP-40 (10%). Several volumes and combinations of chemicals were evaluated (Table 1). Viscosity was observed and subjectively measured with the naked eye while gently agitating the tubes by two researchers in three independent experiments. Relative liquefaction results shown in Table 1 represents the average frequency observed in the six experiments. The “Control” sample (tube #1) was treated according to the digestion-decontamination protocol suggested by WHO with small modifications such as not using phosphate buffer to stop the decontamination process because preservation of M. tuberculosis bacilli for culturing is not the purpose of the present protocol. Hence, NALC/NaOH was added to Tube #1, resulting in complete liquefaction (+). Tube #2 tests if any of the chemicals that will be evaluated would interfere with the standard procedure (NALC/NaOH), and no interference was observed. Triton X-100, SDS, or NP-40 alone or in combination were the least effective chemicals and showed little to no mucin-liquefying power (+++). Urea alone was more effective (++) than in combination with any surfactant (Triton X-100, SDS, or NP-40)(+++), but still without achieving the same level of liquefaction elicited by NALC/NaOH. The only chemical as effective as the control treatment was GSCN (+), either alone or in combination with urea or any of the surfactants (Table 1).

Next, we evaluated six different extraction protocols (Table 2). The protocols varied on punch size (one 6 mm punch, or the whole 11 mm circle), washing and elution buffers (H2O or TE pH 8.0), as well as different incubation conditions (with or without incubation/sonication/vortexing). Mucin samples were spiked with 25 ng/μL of DNA extracted from H37Rv MTB cells. Protocols #3 and #4 showed better results when compared to the others (#1, #2, #5, or #6), as measured by amplification of the IS6110 genomic target on the standard benchtop equipment ABI7500 (Fig 2). Similar result was obtained with the portable system Q3-Plus. Interestingly, using the undiluted extracted DNA resulted in no amplification in neither instrument (Table 4). However, diluting both extracted DNA at 1:10 or 1:100 ratios resulted in positive amplifications, suggesting that some contaminants and inhibitors were present in the undiluted extract (Fig 1 and Table 4). Indeed, the difference of approximately 3–4 Ct values between the 1:10 and 1:100 diluted samples suggest that no inhibitor is present after the dilution. Interestingly, the same pattern was observed with the ready-to-use reactions performed in the portable qPCR instrument. Even though the detection occurred in a later Ct, the IS6110 marker was detected with the expected difference of approximately 3.3 Ct between the 1:10 and 1:100 dilutions. Table 4 summarizes the Ct values obtained for each dilution in protocols #3 and #4. A Student’s t-test analysis of the observed means show that the results obtained with the Q3-Plus system are not significantly different from those obtained with the ABI7500 instrument using either protocol (p-value of 0.16 for protocol #3 and 0.42 for protocol #4, at the 1:10 dilution). Similarly, no significant difference was observed between the regular and the ready-to-use reagents (p-value of 0.22 for protocol #3 and 0.39 for protocol #4, at the 1:10 dilution). However, despite having a similar performance, the gelified results were statistically different than the ones obtained with the regular qPCR format (p-value of 0.02 for protocol #3 and 0.05 for protocol #4, at the 1:10 dilution) (Table 4). Taken together, these results suggest that protocol #3 yields the best results, and therefore it was used in the next experiments.

Fig 2. Representative traces of the qPCR amplification of M. tuberculosis IS6110 target.

Fig 2

Porcine mucin samples spiked with M. tuberculosis H37Rv DNA (25 ng/μL) were processed according to protocols #3 or #4. Traces “a” and “b” were obtained after 1:10 and 1:100 dilution of the eluted DNA obtained with protocol #3. Traces “c” and “d” were obtained after 1:10 and 1:100 dilution of the eluted DNA obtained with protocol #4. “PC” and “NC” represent the positive control (25 ng/μL of DNA extracted from H37Rv MTB cells) and the negative control (TE pH 8.0), respectively. Traces “e”, “f”, “g”, and “h”, (“e–h”) represent 1:100 dilutions of protocols #1, #2, #5, and #6. Traces are representative of at least three independent extraction procedures.

Table 4. Comparison of ABI7500 and Q3 using protocols #3 and #4.

Protocol Dilution ABI7500 –Regular Q3-Plus–Regular Q3-Plus–Gelified
# 3 No dilution Undetermined Undetermined Undetermined
1:10 22.60 ± 0.36 22.10 ± 0.51 24.50 ± 0.91
1:100 25.62 ± 0.60 25.43 ± 0.59 28.52 ± 0.74
# 4 No dilution Undetermined Undetermined Undetermined
1:10 24.45 ± 0.54 24.57 ± 0.63 28.77 ± 1.09
1:100 28.18 ± 0.52 28.53 ± 0.89 34.33 ± 1.16

The two best protocols were compared using a standard benchtop or a portable instrument. Undiluted supernatants did not yield any amplification, while simple 10-fold dilutions in TE pH 8.0 allowed the detection of M. tuberculosis DNA. Cts are shown as mean ± S.D.

Evaluation of FTA extraction protocol with intact MTB cells and colony forming unit counting

Starting from a M. tuberculosis suspension corresponding to the turbidity 1 on the McFarland scale, colony growth could be observed up to the fourth 1:10 dilution. Counting could be performed for the third and fourth dilutions, yielding an average of 15 ± 2.1 and 02 ± 0.7 CFU/ml, respectively (Table 5). PCR performed with the DNA extracted from the corresponding FTA cards using protocol #3 resulted in detection of the IS6110 target for all four dilutions, with the last detected dilution (fourth dilution) displaying a Ct of 33.95 ± 1.02 for the ABI7500 and of 35.90 ± 1.21 for the gelified reaction on the Q3-Plus (Table 5). Representative traces of the qPCR runs on the standard ABI7500 and the portable Q3-Plus instrument detecting DNA obtained from dilution 10−4 are shown in S1 Fig. The S1 Fig also shows a positive control (PC) for detection of 25 ng/μL of DNA extracted from H37Rv MTB cells. The efficiency of the qPCR detection was determined to be 105.4% (slope -3.20 and R2 of 0.997) for the ABI7500 and 125.6% (slope -2.83 and R2 of 0.987) for the Q3-Plus.

Table 5. Colony forming unit and IS6110 detection by two qPCR instruments using 1:10 dilutions of a M. tuberculosis cell suspension.

Dilution Average (CFU/mL) ABI7500 (Ct ± SD) Q3-Plus (Ct ± SD)
10−1 countless 24.13 ± 0.78 27.45 ± 0.56
10−2 countless 27.37 ± 0.83 30.53 ± 0.70
10−3 15.5 30.02 ± 0.91 33.97 ± 0.83
10−4 1.5 33.43 ± 0.71 35.62 ± 0.82
10−5 no growth Undetectable Undetectable

Plates were seeded with the same volume and concentration of M. tuberculosis as FTA Micro Elute cards that were processed according to protocol #3.

Evaluation of the proposed protocol using MTB patients’ samples

All previous results shown here were produced using a concentrated porcine mucin suspension, which has sputum-like consistency [15]. Since sputum contains other substances that might interfere with the qPCR, such as proteases, nucleases, and blood, we sought to evaluate the proposed protocol using patients’ samples. A small convenience sample of 17 patients previously characterized by GeneXpert PCR and culture was selected from a larger cohort.

The untreated samples were submitted to protocol #3, and the extracted DNA was evaluated on the standard (ABI7500) and portable (Q3-Plus) instruments (Table 6). Representative qPCR traces for the analysis of the extracted DNA on the ABI7500 and Q3-Plus instruments are shown in S2 Fig. Panel A shows the detection of the Mycobacterium IS6110 target, the human 18S rRNA target, and a positive control DNA from H37Rv MTB cells (“PC”) on the standard instrument ABI7500. Panel B shows a similar qPCR run on the portable Q3-Plus instrument. A simple characterization as “Positive” or “Negative” for the presence of MTB DNA shows that the new protocol produces the same results as the GeneXpert, with only one sample producing a different result (sample #10). As expected, when GeneXpert results differ from culture, results obtained with protocol #3 differed too (samples #1 and #11). The calculated kappa coefficients show a substantial agreement (88.9%, Cohen’s kappa of 0.77) between the Q3-Plus (or the ABI7500) and the GeneXpert sample characterization, and a moderate agreement (78.9%, Cohen’s kappa of 0.58) between the Q3-Plus (or the ABI7500) and the culture results. Overall, when compared to GeneXpert, the Q3-Plus (or the ABI7500) showed a sensitivity of 90.0% (CI95% 55.5–99.8%), and a specificity of 100% (CI95% 59.1–100.0%). When compared to culture, the Q3-Plus (or the ABI7500) showed a sensitivity of 100% (CI95% 59.0–100.0%), a specificity of 80.0% (CI95%44.4–97.5%). Most importantly, all detections of the human 18S rRNA were within acceptable ranges (13 < Ct > 33, [21]). The concentration of DNA in the eluates produced by applying protocol #3 to the patients’ samples was 36.22 ± 17.17 ng/μL (CI95% 30.53–41.91 ng/μL).

Table 6. Comparison of detection of M. tuberculosis among different platforms.

Sample # Culture GeneXpert ABI7500 Q3-Plus
1 Negative Positive Positive Positive
2 Positive Positive Positive Positive
3 Negative Negative Negative Negative
4 Positive Positive Positive Positive
5 Negative Negative Negative Negative
6 Negative Negative Negative Negative
7 Positive Positive Positive Positive
8 Positive Positive Positive Positive
9 Positive Positive Positive Positive
10 Negative Positive Negative Negative
11 Negative Positive Positive Positive
12 Positive Positive Positive Positive
13 Negative Negative Negative Negative
14 Positive Positive Positive Positive
15 Negative Negative Negative Negative
16 Negative Negative Negative Negative
17 Negative Negative Negative Negative

Selected human samples previously characterized by culture or the benchtop instrument GeneXpert were selected for evaluation using the proposed protocol #3. Reactions on the ABI7500 were performed in triplicates, and on the Q3-Plus in quadruplicates. Characterization as “positive” means at least two of the replicate reactions were positive.

Discussion

In this study, our aim was to demonstrate a proof of concept protocol for a rapid, simple, and cost-effective sample preparation for DNA extraction from samples containing M. tuberculosis. The protocol comprises a paper-based DNA extraction and specific target amplification/detection by a portable and easy-to-use real time PCR platform. An overview of the full procedure is outlined in Fig 3, showing a direct comparison to the general workflow of commercially available spin-column extraction kits. Although the ASSURED requirements have been met to a large extent in platforms such as GeneXpert Ultra or BioFire, the Q3-Plus system shows some advantages over both the aforementioned instruments and the standard benchtop ABI7500 in terms of equipment and reaction costs, reaction volume, user friendly interface, fast temperature ramping, and shorter total reaction time [12, 20]. Some of these features will be further discussed below.

Fig 3. Comparative flowchart of the proposed simplified protocol.

Fig 3

On the left panel, a general procedure for spin-column DNA extraction used in most commercial products. On the right panel, a step-by-step description of the simple and straightforward protocol for POC screening of tuberculosis-suspected samples.

For efficient diagnosis of TB, one must liquefy the sputum to disrupt the complex network of interlinked mucin proteic matrix, which is the main responsible for trapping the target microorganism [23]. Different strategies (chemical, mechanical or a combination of both) can be applied for sputum liquefaction, in a process where it changes from viscous and heterogeneous to a homogenous and liquefied state [4]. In the current study, several chemicals were screened for liquefaction and homogenization of sputum samples such as the chaotropic agents GSCN and urea, or the detergents NP-40, SDS, and Triton X-100. In previous studies, Triton X-100, urea, and GSCN were shown to eliminate all bacteria in sputum samples, including M. tuberculosis [8, 24]. Interestingly, GSCN by itself showed very efficient results in terms of sputum liquefaction, even when combined with the other chemicals. It has been previously shown that concentrated GSCN can be used in sample preparation for the extraction of DNA and protein from a variety of samples [25], and even using an electricity-free protocol [26] or small battery-operated instruments [27]. More importantly, M. tuberculosis was shown to become non-viable after exposure to commercial lysis buffers, which contain concentrated guanidine [8]. This guanidine feature is essential to the protocol developed in the present work, since we propose the sample to be manipulated in low-resource settings, which might not have safety cabinets available for diagnostic routines. Moreover, we suggest that the current protocol should use the whole sample volume in the initial liquefaction step, in order to avoid the known heterogeneity of the sputum samples. In such scenario, samples would be immediately decontaminated by the concentrated guanidine isothiocyanate and M. tuberculosis would be made inviable, presenting no risks for the operator in the subsequent steps. The FTA ELUTE Micro Card, based on Whatman FTA technology, are chemically treated paper cards that enable cell lysis and release of nucleic acids upon contact [28]. Integrating liquefaction and decontamination of the sputum sample to a paper-based DNA extraction is another approach for TB diagnosis adopted in our proposed protocol. Others have demonstrated a rapid and cost-effective sample preparation using a microfluidic “origami”, using spiked mucin [15] or even artificial sputum [27] as models. When compared to the microfluidic “origami”, the FTA card is more efficient in cell lysis and disintegration of the viscous matrix of a sputum sample because of the dry reagents are already stored on the paper. Moreover, the microfluidic “origami” procedure takes around 2 hours while the protocol described here takes 1.5 hours from raw sample to eluted DNA. The semi-automated PureLyse® protocol, although as fast as our protocol, does not show the same sensitivity [27]. Interestingly, the use of FTA cards for storage, transport and preservation of sputum samples has been used successfully for diagnosis of MTB [29, 30]. These authors have shown that MTB DNA was stable in the FTA card for six months at room temperature [29], and that the extracted DNA is still suitable for PCR [30]. The findings provide not only a simple and economically favorable solution for collection, storage and transportation of the sputum but also suggest the use of these cards for sample preparation and DNA extraction in low-income countries such as the protocol described in the present work.

In the present study, we chose to use IS6110, a M. tuberculosis complex genomic marker. This target is widely used in diagnostic and epidemiologic studies due to high number of copies (up to 25) and high discriminatory ability. Although some studies have shown M. tuberculosis isolates with lower number of IS6110 copies, this genomic marker is considered one of the best options to increase the sensibility of diagnostic tests. Indeed, the inclusion of the genomic sequences IS6110 and S1081 in the new generation of the GenXpert MTB/Rif test resulted in increased sensibility [3136].

The low number of samples analyzed in the present study limits our ability to draw definitive conclusions, but the results obtained with the optimized protocol showed good agreement with results obtained by reference diagnosis methods such as culture or other molecular tests, providing the basis for future studies. The ready-to-use reactions performed similarly to the conventional ones, exhibiting similar lower detection limits, as previously shown for detection of T. cruzi or Plasmodium spp DNA [12]. After evaluation of larger cohorts, we suggest that the ready-to-use reactions could be implemented in places with unreliable power supply, as in urban suburbs and rural areas of high TB burden countries of Brazil, India, Indonesia, China, Philippines and Pakistan. The insertion of an internal control in the reaction, i.e. the detection of the human 18S rRNA gene, assures the functionality of the system regarding sample extraction, nucleic acid integrity, the absence of inhibitors in the reaction, and correct functioning of equipment and software [12, 21].

For comparison purposes, the cost of DNA extraction with a commercial kit is about US$3–5 per sample, while the cost of our extraction protocol using GSCN+FTA paper can be roughly estimated at US$1–2 per sample. The cost of the PCR reaction per patient using the Q3-plus instrument and ABI 7500 is similar (US$3–4) while there is a significant difference in the cost of the instrument (Q3-plus <US$10,000 while ABI7500 >US$40,000) [12, 20]. In general, the ABI7500 or any other benchtop instrument needs skilled professionals, a sophisticated lab environment and routine maintenance and calibration, while the Q3-Plus platform relies on minimum personal training and does not require maintenance/calibration or any other lab infrastructure.

Turnaround time is also an important aspect of any diagnostic assay. The culture technique, which is the standard for MTB diagnosis, can take from 4 to 16 weeks [37], and such a long period can result in further complexities such as delays in initiation of the treatment or loss of disease follow up. On the other hand, GeneXpert Ultra have turnaround time of 80–90 min but have relatively high cost per sample (concessional price with up to 90% discount is US$9.98 for eligible countries). We have estimated the turnaround time for our tests as 3 hours from raw sample to result. This feature provides a rapid diagnosis that, thanks to the accurate molecular detection elicited by qPCR, leads to an early and more efficient start of treatment. Our assay reagents are workable at room temperature without the need for any special storage infrastructure, which makes tuberculosis diagnosis feasible in poorly equipped areas. Furthermore, access to quality diagnosis at POC will not only allow timely initiation of treatment but also reduce the dropout rate of the patients, which is one of the key factors for the spread of TB [2].

It should be stressed that the results are presented herein as a proof of concept, and that the protocol and reported LOD must be evaluated in larger cohorts. Another important aspect of the proof of concept protocol is that it was developed using an artificial matrix, as other have already done [15]. However, when evaluated with real sputum samples, the results were not different from those obtained with a reference molecular method (Table 6), suggesting that any possibly present inhibitors did not impair the qPCR detection of M. tuberculosis DNA.

Conclusions

The present work shows the development of a simple and inexpensive sample preparation protocol for the detection of TB in viscous sputum sample, integrated with an easy-to-use portable real time PCR system, thus comprising a simple sample-to-answer diagnostic tool. Our sample preparation protocol allows the detection of a MTB bacterial load as low as 02 CFU/mL. The work presented here is a step towards a point of care solution for MTB diagnosis, suitable for low infrastructure primary health units as well as secondary healthcare clinics.

Supporting information

S1 Fig. Representative traces of the qPCR detection of DNA extracted from the smallest dilution that produced countable colonies.

Panel A, trace obtained on the standard ABI7500 with DNA from dilution 10−4. Panel B, trace obtained on the portable Q3-Plus with DNA from dilution 10−4.

(PDF)

S2 Fig. Representative traces of the qPCR detection of DNA extracted from a positive patient sample.

Shown is the detection of the positive control (PC) or the IS6110 target (blue lines) and the human 18S target (red lines). Panel A, trace obtained on the standard ABI7500. Panel B, trace obtained on the portable Q3-Plus.

(PDF)

S1 Table. Data used to calculate the averages presented on Table 4.

(DOCX)

S2 Table. Data used to calculate the averages presented on Table 5.

(DOCX)

Acknowledgments

The authors would like to thank Dr. Thiago Jacomasso for valuable input during writing of the manuscript, and Mr. Nilson Fidêncio and Ms. Silvia Bohn for the excellent technical assistance.

Data Availability

All relevant data are within the paper and its Supporting Information files. Some data cannot be shared publicly because they might contain patient information. However, these data can be obtained upon request by contacting the Ethics Committee of the Universidade Luterana do Brasil at the email comitedeetica@ulbra.br.

Funding Statement

Several authors received grants or fellowships from the Brazilian funding agencies CNPq and CAPES. This work was funded by a grant from the Banco Nacional de Desenvolvimento Econômico e Social (BNDES), contract no. 15.2.0473.1 (Operation #4.816.864), and by a grant from the Fundação de Amparo à Pesquisa do Rio Grande do Sul (FAPERGS grant #17/2551-0001542-8). There was no additional external funding received for this study. IBMP, BNDES, FAPERGS, CAPES or CNPq had no participation in the present study’s design, data collection, analysis or interpretation, or writing of the report and decision to submit for publication.

References

  • 1.World Health Organization. Global Tuberculosis Report. Licence: CC BY-NC-SA 3.0 IGO, editor. Geneva: World Health Organization; 2019.
  • 2.Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis. 2018;18: e199–e210. 10.1016/S1473-3099(18)30111-7 [DOI] [PubMed] [Google Scholar]
  • 3.Machado D, Couto I, Viveiros M. Advances in the molecular diagnosis of tuberculosis: From probes to genomes. Infect Genet Evol. 2019;72: 93–112. 10.1016/j.meegid.2018.11.021 [DOI] [PubMed] [Google Scholar]
  • 4.Ali N, Cássia R De, Rampazzo P, Dias A, Costa T, Krieger MA. Current Nucleic Acid Extraction Methods and Their Implications to Point-of-Care Diagnostics. Biomed Res Int. 2017;2017: 1–13. 10.1155/2017/9306564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kubica GP, Dye WE, Cohn ML, Middlebrook G. Sputum Digestion and Decontamination With N-acetyl-L-cysteine-sodium Hydroxide for Culture of Mycobacteria. Am Rev Respir Dis. 1963;87: 775–9. 10.1164/arrd.1963.87.5.775 [DOI] [PubMed] [Google Scholar]
  • 6.Stop TB Partnership. Mycobacteriology Laboratory manual. In: Global Laboratory Initiative [Internet]. 2014 [cited 26 Feb 2020] p. 147. Available: http://www.stoptb.org/wg/gli/assets/documents/gli_mycobacteriology_lab_manual_web.pdf
  • 7.Ashraf Kharaz Y, Zamboulis D, Sanders K, Comerford E, Clegg P, Peffers M. Comparison between chaotropic and detergent-based sample preparation workflow in tendon for mass spectrometry analysis. Proteomics. 2017;17: 1700018 10.1002/pmic.201700018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Clinghan R, Anderson TP, Everett V, Murdoch DR. Viability of Mycobacterium tuberculosis after processing with commercial nucleic acid extraction kits. J Clin Microbiol. 2013;51: 2010 10.1128/JCM.00923-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Huckle D. The impact of new trends in POCTs for companion diagnostics, non-invasive testing and molecular diagnostics. Expert Rev Mol Diagn. 2015;15: 815–827. 10.1586/14737159.2015.1033405 [DOI] [PubMed] [Google Scholar]
  • 10.Wang S, Lifson MA, Inci F, Liang L-G, Sheng Y-F, Demirci U. Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings. Expert Rev Mol Diagn. 2016;16: 449–59. 10.1586/14737159.2016.1142877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Rampazzo RDCP, Solcà MDS, Santos LCS, Pereira LDN, Guedes JCO, Veras PST, et al. A ready-to-use duplex qPCR to detect Leishmania infantum DNA in naturally infected dogs. Vet Parasitol. 2017;246 10.1016/j.vetpar.2017.09.009 [DOI] [PubMed] [Google Scholar]
  • 12.Rampazzo RCP, Graziani AC, Leite KK, Surdi JA, Biondo CA, Costa MLN, et al. Proof of Concept for a Portable Platform for Molecular Diagnosis of Tropical Diseases. J Mol Diagnostics. 2019;21: 839–851. 10.1016/j.jmoldx.2019.04.008 [DOI] [PubMed] [Google Scholar]
  • 13.Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012;9: e1001306 10.1371/journal.pmed.1001306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Eisenach KD, Cave MD, Bates JH, Crawford JT. Polymerase chain reaction amplification of a repetitive DNA sequence specific for Mycobacterium tuberculosis. J Infect Dis. 1990;161: 977–981. 10.1093/infdis/161.5.977 [DOI] [PubMed] [Google Scholar]
  • 15.Govindarajan a. V., Ramachandran S, Vigil GD, Yager P, Böhringer KF. A low cost point-of-care viscous sample preparation device for molecular diagnosis in the developing world; An example of microfluidic origami. Lab Chip. 2012;12: 174–181. 10.1039/c1lc20622b [DOI] [PubMed] [Google Scholar]
  • 16.Brasil M da S. Manual nacional de vigilância laboratorial da tuberculose e outras micobactérias. Brasília: Ministério da Saúde; 2008. [Google Scholar]
  • 17.Rosado PMFS, López GL, Seiz AM, Alberdi MM. Method for preparing stabilised reaction mixtures, which are totally or partially dried, comprising at least one enzyme, reaction mixtures and kits containing said mixtures. World Intellectual Property Organization (WIPO); 2002. p. 75. doi:WO 02/072002A3 [Google Scholar]
  • 18.Sun Y, Høgberg J, Christine T, Florian L, Monsalve LG, Rodriguez S, et al. Pre-storage of gelified reagents in a lab-on-a-foil system for rapid nucleic acid analysis. Lab Chip. 2013;13: 1509–14. 10.1039/c2lc41386h [DOI] [PubMed] [Google Scholar]
  • 19.Iglesias N, Subirats M, Trevisi P, Ramírez-Olivencia G, Castán P, Puente S, et al. Performance of a new gelled nested PCR test for the diagnosis of imported malaria: comparison with microscopy, rapid diagnostic test, and real-time PCR. Parasitol Res. 2014;113: 2587–91. 10.1007/s00436-014-3911-z [DOI] [PubMed] [Google Scholar]
  • 20.Cereda M, Cocci A, Cucchi D, Raia L, Pirola D, Bruno L, et al. Q3: A Compact Device for Quick, High Precision qPCR. Sensors. 2018;18: 2583 10.3390/s18082583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Manta FS de N, Leal-Calvo T, Moreira SJM, Marques BLC, Ribeiro-Alves M, Rosa PS, et al. Ultra-sensitive detection of Mycobacterium leprae: DNA extraction and PCR assays. PLoS Negl Trop Dis. 2020;14: e0008325 10.1371/journal.pntd.0008325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. Biometrics. 1977;33: 159 10.2307/2529310 [DOI] [PubMed] [Google Scholar]
  • 23.Allen V, Nicol MP, Tow LA. Sputum processing prior to Mycobacterium tuberculosis detection by culture or nucleic acid amplification testing: a narrative review. Res Rev J Microbiol Biotechnol. 2016;5: 96–108. [Google Scholar]
  • 24.Khan IUH, Yadav JS. Development of a single-tube, cell lysis-based, genus-specific PCR method for rapid identification of mycobacteria: optimization of cell lysis, PCR primers and conditions, and restriction pattern analysis. J Clin Microbiol. 2004;42: 453–7. 10.1128/jcm.42.1.453-457.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Sambrook J, Russell D. Molecular Cloning: A Laboratory Manual. 3rd ed Cold Spring Harbor Laboratory Press; 2001. [Google Scholar]
  • 26.Pawlowski DR, Karalus RJ. Electricity-Free, Sequential Nucleic Acid and Protein Isolation. J Vis Exp. 2012; 3–9. 10.3791/4202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ferguson TM, Weigel KM, Lakey Becker A, Ontengco D, Narita M, Tolstorukov I, et al. Pilot study of a rapid and minimally instrumented sputum sample preparation method for molecular diagnosis of tuberculosis. Sci Rep. 2016;6: 19541 10.1038/srep19541 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.de Vargas Wolfgramm E, de Carvalho FM, da Costa Aguiar VR, De Nadai Sartori MP, Hirschfeld-Campolongo GCR, Tsutsumida WM, et al. Simplified buccal DNA extraction with FTA®Elute Cards. Forensic Sci Int Genet. 2009;3: 125–127. 10.1016/j.fsigen.2008.11.008 [DOI] [PubMed] [Google Scholar]
  • 29.Guio H, Okayama H, Ashino Y, Saitoh H, Xiao P, Miki M, et al. Method for efficient storage and transportation of sputum specimens for molecular testing of tuberculosis. Int J Tuberc Lung Dis. 2006;10: 906–910. [PubMed] [Google Scholar]
  • 30.Castan P, de Pablo A, Fernandez-Romero N, Rubio JM, Cobb BD, Mingorance J, et al. Point-of-Care System for Detection of Mycobacterium tuberculosis and Rifampin Resistance in Sputum Samples. J Clin Microbiol. 2014;52: 502–507. 10.1128/JCM.02209-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sankar S, Kuppanan S, Balakrishnan B, Nandagopal B. Analysis of sequence diversity among IS6110 sequence of Mycobacterium tuberculosis: possible implications for PCR based detection. Bioinformation. 2011;6: 283–285. 10.6026/97320630006283 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Spositto FLE, Campanerut PAZ, Ghiraldi LD, Leite CQF, Hirata MH, Hirata RDC, et al. Multiplex-PCR for differentiation of Mycobacterium bovis from Mycobacterium tuberculosis complex. Brazilian J Microbiol. 2014;45: 841–843. 10.1590/s1517-83822014000300012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Reed JL, Basu D, Butzler MA, McFall SM. XtracTB Assay, a Mycobacterium tuberculosis molecular screening test with sensitivity approaching culture. Sci Rep. 2017;7: 3653 10.1038/s41598-017-03930-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Arora J, Suresh N, Porwal C, Pandey P, Pande JN, Singh UB. Genotyping Mycobacterium tuberculosis isolates with few copies of IS6110: Value of additional genetic markers. Infect Genet Evol. 2020;81: 104230 10.1016/j.meegid.2020.104230 [DOI] [PubMed] [Google Scholar]
  • 35.Kolia-Diafouka P, Godreuil S, Bourdin A, Carrère-Kremer S, Kremer L, Van de Perre P, et al. Optimized Lysis-Extraction Method Combined With IS6110-Amplification for Detection of Mycobacterium tuberculosis in Paucibacillary Sputum Specimens. Front Microbiol. 2018;9 10.3389/fmicb.2018.02224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Millán-Lou MI, López-Calleja AI, Colmenarejo C, Lezcano MA, Vitoria MA, del Portillo P, et al. Global Study of IS 6110 in a Successful Mycobacterium tuberculosis Strain: Clues for Deciphering Its Behavior and for Its Rapid Detection. J Clin Microbiol. 2013;51: 3631–3637. 10.1128/JCM.00970-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Aziz M, Ryszewska K, Blanc L, Vincent V, Getahun H, Wright A, et al. Expanding culture and drug susceptibility testing capacity in tuberculosis diagnostic services: The new challenge. Int J Tuberc Lung Dis. 2007;11: 247–250. [PubMed] [Google Scholar]

Decision Letter 0

Seyed Ehtesham Hasnain

28 Aug 2020

PONE-D-20-24367

Demonstration of a fast and easy sample-to-answer protocol for tuberculosis screening in point-of-care settings: a proof of concept study §

PLOS ONE

Dear Dr. Costa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 12 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Hasnain Seyed Ehtesham

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you state "Various ratios of sample to the liquefying solutions were evaluated, and the best results were obtained by mixing one volume of sputum sample to 0.4 volumes of Solution 01 (not shown)." Unfortunately, reference to unpublished or unshown data does not meet our data availability criteria (https://journals.plos.org/plosone/s/data-availability). Please either provide this data in the manuscript or a public repository, or if the data is not essential for your study, you may remove it.

3.  We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4. Thank you for stating in your Funding Statement:

"This work was partially funded by a grant from the Banco Nacional de

Desenvolvimento Econômico e Social (BNDES - bndes.gov.br), contract no.

15.2.0473.1 (Operation #4.816.864) to ADTC. The funders had no role in study design,

data collection and analysis, decision to publish, or preparation of the manuscript."

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

5. Thank you for stating the following in the Competing Interests section:

"I have read the journal's policy and the authors of this manuscript have the following

competing interests: authors NA, MAK, and ADTC are affiliated with Instituto de

Biologia Molecular do Paraná (IBMP), producer of the PCR mastermix used in the

qPCR experiments."

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

6. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

7. We note that your paper includes detailed descriptions of individual patients (In figure 2). As per the PLOS ONE policy (http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research) on papers that include identifying, or potentially identifying, information, the individual(s) or parent(s)/guardian(s) must be informed of the terms of the PLOS open-access (CC-BY) license and provide specific permission for publication of these details under the terms of this license. Please download the Consent Form for Publication in a PLOS Journal (http://journals.plos.org/plosone/s/file?id=8ce6/plos-consent-form-english.pdf). The signed consent form should not be submitted with the manuscript, but should be securely filed in the individual's case notes. Please amend the methods section and ethics statement of the manuscript to explicitly state that the patient/participant has provided consent for publication: “The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details”.

Additional Editor Comments (if provided):

Major Revision

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: • Authors need to thoroughly rewrite methodology of the study for more clarity.

• Authors should clearly mention the patient’s enrollment in the study whether patients were new cases or previously treated cases, exclusion and inclusion criteria of the patients enrolled, in methodology section.

• Line no. 176, authors need to clearly define the term “non-TB patients”.

• Authors should clearly mention the volume of sputum sample collected from each patient and clearly state whether that the informed consent has been taken from each patient.

• According to the WHO guidelines for TB diagnosis, sputum samples are needed to be collected for two consecutive days. In the present study, how the sputum samples have been collected? Whether these samples were from day 1 or day 2 or pooled? The author should clearly mention the collection of sputum samples from the patients enrolled.

• Author should provide schematic diagram of study design for more clarity.

• The study has smaller number of samples to be compared to give any conclusion.

• Author may provide supplementary file of data for more clarity.

• Authors have chosen the Insertion Sequence IS6110 from Mycobacterium tuberculosis complex as genomic marker. However, insertion sequence IS6110 of MTB has limitation of variable number of copies from multiple to single in different isolates. Author should discuss this issue in the study.

• Authors should share the load of human DNA in each sample and the data obtained after RT-PCR and may provide supplementary file of data.

Reviewer #2: The manuscript “Demonstration of a fast and easy sample-to-answer protocol for tuberculosis screening in point-of-care settings: a proof of concept study” provides minor but important improvisation in the TB diagnostics. Their instrument free DNA sample preparation from sputum with long term stability may have wider application in the future. I have following suggestions

1. As presented in the table-1, qualitative determination of sample viscosity by visualisation should be performed by more than one researcher and classification with maximum frequency should be presented for better reliability.

2. PCR results from new paper-based DNA isolation vs classical DNA isolation should be performed using same set of patient samples and gel image should be given in the manuscript.

3. At line 185-189, specific and exact composition and protocol of the sample liquefication is not mention. As this is the whole basis of this manuscript, the said paragraph must be re-written for clarity and reproducibility. Just mentioning “Solution 01 (not shown)” is not sufficient.

4. Similar to the last point, modify the line 220-222, the ambiguity caused my mysterious solution-1 without specific details.

5. As per line 223-224, ‘The most efficient DNA extraction protocol as determined in section “DNA elution protocols’; the most efficient protocol must be identified and stated in the paragraph.

6. Impact of gelification clubbed with new DNA extraction should be compared with classical protocols and gel image should be attached in the manuscript.

7. In line 242-243, specific and complete description of final working gelification solution and protocol must be given.

8. In the discussion, line 454-459, the detail itself is incorrect and must be removed. As given in the manuscript, “This raises another question: since qPCR detects DNA sequences, dead bacilli would also be detected and, therefore, this screening tool is not suitable for detecting active TB infections. However, the presence of MTB DNA in the sample is indicative of close contact to a TB patient, if not a latent infection itself...... to the culture”. The point discussed is absurd.

9. None of the figures (gel photo of PCR band or graph of RT-PCT) from the experiments displays the sensitivity of new method and its comparison with old methods.

10. As asserted previously, this manuscript presents a new and minor improvisation in the method and TB detection. If exact compositions and protocols of different steps are not given then, the whole purpose of presenting the manuscript to scientific world will become futile, worthless and unpublishable.

11. Make improvisation in language for error-free writing with better consistency and flow.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Dec 14;15(12):e0242408. doi: 10.1371/journal.pone.0242408.r002

Author response to Decision Letter 0


19 Oct 2020

Dear Editor and Reviewers,

Please find below a detailed response to all points raised in the review process. We greatly appreciate the comments and suggestions and truly believe that the manuscript is improved.

Sincerely,

Alexandre Costa

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Reply: We have made all efforts to ensure that the manuscript meets all PLOS ONE's style requirements.

2. We note that you state "Various ratios of sample to the liquefying solutions were evaluated, and the best results were obtained by mixing one volume of sputum sample to 0.4 volumes of Solution 01 (not shown)." Unfortunately, reference to unpublished or unshown data does not meet our data availability criteria (https://journals.plos.org/plosone/s/data-availability). Please either provide this data in the manuscript or a public repository, or if the data is not essential for your study, you may remove it.

Reply: The data is not essential to the study and the sentence was removed.

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Reply: We have changed the sentence and all data are now contained in the manuscript. However, detailed GeneXpert MTB/Rif data beyond the classification “positive” or “negative” cannot be published due to restrictions imposed by the ethics committee since these data were obtained from patient charts. These data can be obtained upon request to the Ethics Committee of the Universidade Luterana do Brasil at the email comitedeetica@ulbra.br (lines 577-580).

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reply: Some data cannot be publicized and can be accessed by contacting the Ethics Committee of the Universidade Luterana do Brasil at the email comitedeetica@ulbra.br, as stated on reply to item #3. This information is now present in the text (lines 577-580). All data supporting the manuscript is contained in the manuscript, figures, tables and supplementary tables.

4. Thank you for stating in your Funding Statement:

"This work was partially funded by a grant from the Banco Nacional de Desenvolvimento Econômico e Social (BNDES - bndes.gov.br), contract no. 15.2.0473.1 (Operation #4.816.864) to ADTC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

Reply: Funding statement has been amended in the cover letter, as requested.

5. Thank you for stating the following in the Competing Interests section: "I have read the journal's policy and the authors of this manuscript have the following competing interests: authors NA, MAK, and ADTC are affiliated with Instituto de Biologia Molecular do Paraná (IBMP), producer of the PCR mastermix used in the qPCR experiments."

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

Reply: The requested statement has been added to the cover letter.

6. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

Reply: The ethics statement has been moved to Methods (lines 134-138).

7. We note that your paper includes detailed descriptions of individual patients (In figure 2). As per the PLOS ONE policy (http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research) on papers that include identifying, or potentially identifying, information, the individual(s) or parent(s)/guardian(s) must be informed of the terms of the PLOS open-access (CC-BY) license and provide specific permission for publication of these details under the terms of this license. Please download the Consent Form for Publication in a PLOS Journal (http://journals.plos.org/plosone/s/file?id=8ce6/plos-consent-form-english.pdf). The signed consent form should not be submitted with the manuscript, but should be securely filed in the individual's case notes. Please amend the methods section and ethics statement of the manuscript to explicitly state that the patient/participant has provided consent for publication: “The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details”.

Reply: Figure 2 does not contain detailed descriptions of individual patients. The inscriptions within the figure do not pertain to any patient and are merely illustrative.

Additional Editor Comments (if provided):

Major Revision

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1:

• Authors need to thoroughly rewrite methodology of the study for more clarity.

Reply: Some sections in Methods have been rewritten and more information has been added.

• Authors should clearly mention the patient’s enrollment in the study whether patients were new cases or previously treated cases, exclusion and inclusion criteria of the patients enrolled, in methodology section.

• Line no. 176, authors need to clearly define the term “non-TB patients”.

• Authors should clearly mention the volume of sputum sample collected from each patient and clearly state whether that the informed consent has been taken from each patient.

Reply: Patient’s exclusion and inclusion criteria are now clearly stated (lines 127-130). Patients were enrolled by attendance to the Department of Thisiology and Leprosy of the city of Canoas (RS, Brazil). Informed consent was not required by the Ethics Committee since the samples would be discarded (lines 136-137). Non-TB patients were defined by negative results in culture and GeneXpert analyses (lines 132-134). Volume of sputum collected from each patient is now clearly stated as an inclusion criteria (line 129).

• According to the WHO guidelines for TB diagnosis, sputum samples are needed to be collected for two consecutive days. In the present study, how the sputum samples have been collected? Whether these samples were from day 1 or day 2 or pooled? The author should clearly mention the collection of sputum samples from the patients enrolled.

Reply: Samples were collected in two consecutive days, according to WHO guidelines. Characterization by the GeneXpert MTB/Rif assay and culture were performed on day 1 samples. The remaining of the day 1 sample was pooled with the day 2 sample, which was then evaluated by the new paper-based protocol. This information is now shown in lines 130-132.

• Author should provide schematic diagram of study design for more clarity.

Reply: A schematic diagram of the study workflow is now presented as Figure 1.

• The study has smaller number of samples to be compared to give any conclusion.

Reply: We agree with the reviewer that the study was conducted with a small number of samples, and this has been mentioned in the discussion (lines 519-522). This is one of the main reasons we specified in title and discussion that the present study is a proof of concept and not a validation study (lines 554-555). Accordingly, the study does not intend to provide a definitive side-by-side comparison of the methods, but rather to demonstrate the feasibility of the method, as a proof of concept. As stated on lines 519-522 and 554-555, we believe that the demonstration of the feasibility of the method warrants the design of a study on a larger cohort that will allow a definitive conclusion.

• Author may provide supplementary file of data for more clarity.

Reply: A figure showing the qPCR traces of the lowest detectable concentration (dilution 10-4, Table 5) as well as representative traces from a TB-positive sample is provided as supporting data (S1 Fig). We will gladly provide any other data upon a more specific request.

• Authors have chosen the Insertion Sequence IS6110 from Mycobacterium tuberculosis complex as genomic marker. However, insertion sequence IS6110 of MTB has limitation of variable number of copies from multiple to single in different isolates. Author should discuss this issue in the study.

Reply: We agree with the reviewer and have now discussed this issue (lines 512-518).

• Authors should share the load of human DNA in each sample and the data obtained after RT-PCR and may provide supplementary file of data.

Reply: We have added information about the average of the DNA concentration obtained from the patient samples (lines 442-443), which was found to be 36.22 ± 17.17 ng/µL. As stated in Methods (lines 289 and 292), 1 or 5 µL of the extracted DNA (for the portable or the standard instrument) were added to the qPCR reactions, thus representing roughly 7.3 ng/µL total DNA per reaction. It should be noted, however, that the exact amount of human DNA present in each sample is not possible to be calculated, since we also do not know how much M. tuberculosis DNA is present. Representative traces of the qPCR runs on the standard ABI7500 and the portable Q3-Plus instruments are shown in Supplementary Figures.

Reviewer #2:

The manuscript “Demonstration of a fast and easy sample-to-answer protocol for tuberculosis screening in point-of-care settings: a proof of concept study” provides minor but important improvisation in the TB diagnostics. Their instrument free DNA sample preparation from sputum with long term stability may have wider application in the future. I have following suggestions

1. As presented in the table-1, qualitative determination of sample viscosity by visualisation should be performed by more than one researcher and classification with maximum frequency should be presented for better reliability.

Reply: We regret that this information was not present in the initial text. Qualitative determination of sample viscosity by visualization was performed by two researchers (NA and ADTC) in three independent experiments per researcher. The relative viscosity was similar in all six experiments. This information is now given in lines 160-163 and 329-332.

2. PCR results from new paper-based DNA isolation vs classical DNA isolation should be performed using same set of patient samples and gel image should be given in the manuscript.

Reply: All patient samples were analyzed by both methods, the new paper-based method as well as by the GeneXpert MTB/Rif test. We understand that the GeneXpert test represents the classical DNA isolation methods. We regret that we cannot supply the qPCR plots generated by the GeneXpert analysis because they are part of patients’ charts and were restricted by the Ethics Committee. In addition, we would like to mention that we did not perform conventional PCR on any of the samples, and therefore we are not able to supply any gel images. However, we have included a representative qPCR for a patient sample, obtained with both instruments evaluated by the new protocol (ABI7500 and Q3-Plus) (Supplementary Figure 2).

3. At line 185-189, specific and exact composition and protocol of the sample liquefication is not mention. As this is the whole basis of this manuscript, the said paragraph must be re-written for clarity and reproducibility. Just mentioning “Solution 01 (not shown)” is not sufficient.

Reply: The specific and exact composition of all eight solutions evaluated as “Solution 01” are described on lines 151-191, and Table 1. The paragraph was re-written.

4. Similar to the last point, modify the line 220-222, the ambiguity caused my mysterious solution-1 without specific details.

Reply: We are sorry for the ambiguity and believe that it is now resolved by stating that the Solution 01 with the best liquefying ability is GSCN 6M, as shown in lines 201-204 and by the results in Table 1.

5. As per line 223-224, ‘The most efficient DNA extraction protocol as determined in section “DNA elution protocols’; the most efficient protocol must be identified and stated in the paragraph.

Reply: We regret that this information was present only in the description of Table 2. The most efficient DNA extraction protocol was #3, and is now clearly mentioned on line 243-244.

6. Impact of gelification clubbed with new DNA extraction should be compared with classical protocols and gel image should be attached in the manuscript.

Reply: The impact of the gelification on the new DNA extraction protocol was compared with the regular qPCR format in the portable and the standard instrument ABI7500 on Table 4. It was found that the gelification has an impact of 3-4 Ct on the detection by qPCR, but without impact on the ability of the reaction to detect the presence of the genomic target. This shift has also been in other reactions using the same portable instrument when compared to the standard instrument ABI7500 (Rampazzo et al 2019). This information is now included in the discussion (lines 522-524).

7. In line 242-243, specific and complete description of final working gelification solution and protocol must be given.

Reply: Final concentration of each component of the gelification mixture is now given on lines 267-269. Volume of the gelification mixture used in the qPCR mix is stated on line 270-271.

8. In the discussion, line 454-459, the detail itself is incorrect and must be removed. As given in the manuscript, “This raises another question: since qPCR detects DNA sequences, dead bacilli would also be detected and, therefore, this screening tool is not suitable for detecting active TB infections. However, the presence of MTB DNA in the sample is indicative of close contact to a TB patient, if not a latent infection itself...... to the culture”. The point discussed is absurd.

Reply: The text was removed as requested.

9. None of the figures (gel photo of PCR band or graph of RT-PCT) from the experiments displays the sensitivity of new method and its comparison with old methods.

Reply: The sensitivity of the new method was compared to culture using two instruments (see Table 5). Representative qPCR traces of the lowest detectable dilution (10-4, Table 5) are shown as Supplementary Figure 1.

10. As asserted previously, this manuscript presents a new and minor improvisation in the method and TB detection. If exact compositions and protocols of different steps are not given then, the whole purpose of presenting the manuscript to scientific world will become futile, worthless and unpublishable.

Reply: The steps for the preparation of all solutions as well as their exact composition (lines 151-191, and Table 1), and the steps of each protocol (lines 208-222, and Table 2) evaluated are present in the manuscript. We kindly ask the reviewer to point to any information that may have escaped our revision of the manuscript so that this oversight can be corrected.

11. Make improvisation in language for error-free writing with better consistency and flow.

Reply: The final manuscript was thoroughly revised for English spelling, grammar, and flow.

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reply: We greatly appreciate the comments and suggestions of the reviewers, and regret their decision to not disclose their identities as part of the peer review process.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Seyed Ehtesham Hasnain

3 Nov 2020

Demonstration of a fast and easy sample-to-answer protocol for tuberculosis screening in point-of-care settings: a proof of concept study §

PONE-D-20-24367R1

Dear Dr. Costa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I have gone through this revised manuscript and also the Authors response to reviewers comments. There were several issues raised by the Reviewers and Authors have comprehensively addressed all the issues. A schematic diagram of the study workflow is now presented as Figure 1 by the Authors. Revised manuscript shows a new and minor improvisation in the method and TB detection. Authors have now clearly stated the exclusion and inclusion criteria. As pointed out by the Reviewers, Authors have now described the specific and exact composition of all eight solutions evaluated as “Solution 01” and re-written that paragraph. The manuscript has now been revised extensively including making corrections and also other issues. I recommend this manuscript for publication.

Reviewers' comments:

Acceptance letter

Seyed Ehtesham Hasnain

16 Nov 2020

PONE-D-20-24367R1

Demonstration of a fast and easy sample-to-answer protocol for tuberculosis screening in point-of-care settings: a proof of concept study §

Dear Dr. Costa:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Representative traces of the qPCR detection of DNA extracted from the smallest dilution that produced countable colonies.

    Panel A, trace obtained on the standard ABI7500 with DNA from dilution 10−4. Panel B, trace obtained on the portable Q3-Plus with DNA from dilution 10−4.

    (PDF)

    S2 Fig. Representative traces of the qPCR detection of DNA extracted from a positive patient sample.

    Shown is the detection of the positive control (PC) or the IS6110 target (blue lines) and the human 18S target (red lines). Panel A, trace obtained on the standard ABI7500. Panel B, trace obtained on the portable Q3-Plus.

    (PDF)

    S1 Table. Data used to calculate the averages presented on Table 4.

    (DOCX)

    S2 Table. Data used to calculate the averages presented on Table 5.

    (DOCX)

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files. Some data cannot be shared publicly because they might contain patient information. However, these data can be obtained upon request by contacting the Ethics Committee of the Universidade Luterana do Brasil at the email comitedeetica@ulbra.br.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES